Welcome to our dedicated page for Ehave news (Ticker: EHVVF), a resource for investors and traders seeking the latest updates and insights on Ehave stock.
Ehave Inc (EHVVF) delivers cutting-edge mental health informatics solutions through its Ehave Connect platform, empowering clinicians with data-driven decision tools. This news hub provides investors and healthcare professionals with essential updates on the company's clinical advancements and market position.
Access verified press releases, partnership announcements, and operational developments related to ADHD care optimization and medical cannabis treatment validation. Our curated collection includes earnings reports, technology licensing updates, and regulatory milestones that shape Ehave's role in digital healthcare innovation.
Key content categories cover strategic collaborations with medical institutions, platform enhancement disclosures, and financial performance communications. Stay informed about initiatives integrating diagnostic analytics with patient management systems across mental health ecosystems.
Bookmark this page for direct access to primary source materials from Ehave's leadership team. Regularly updated content ensures timely awareness of developments impacting the company's growth in healthcare technology markets.
AIBotics, a subsidiary of Ehave (OTC: EHVVF), has announced plans to launch Phill Robot™, the world's first AI-powered massage robot, in Q2 2025. The device features a patented foldable arm with a 35-inch range and 15-pound massage force, doubling as a nightstand when not in use.
The company's Indiegogo crowdfunding campaign reached its goal in just 24 minutes, demonstrating strong market interest. AIBotics is currently negotiating to implement a pilot program in a premium fitness and wellness facility's recovery lounges in Miami.
The company is targeting multiple growing markets: The Massage Equipment Market ($23.86B in 2023, projected $41.18B by 2032), AI Industrial Robotics Market (expected $64.35B by 2030 with 24.8% CAGR), and Global AI Market (forecasted to grow from $638B in 2024 to $3.6T by 2034).
AIBotics (OTC: AIBT), a subsidiary of Ehave (OTC: EHVVF), has partnered with GMF Ventures to develop UI/UX for Phill Robot, an AI-powered massage robot. The agreement includes developing iOS and Android apps and a website to enhance user experience. Phill Robot features a patented foldable arm with 35-inch reach and 15-pound massage force, integrating with smartphones and smart devices.
The robot's Indiegogo campaign reached its funding goal in 24 minutes, with a launch price of $2,199 (final MSRP: $3,499). AIBotics plans revenue through direct-to-consumer sales, B2B partnerships, and bulk distribution. The company also announced a Letter of Intent to acquire DigiTrax Entertainment in a $40 million deal, including seven patents and a $9 million music catalog.
Mycotopia Therapies Inc., a subsidiary of Ehave (OTC: EHVVF), has announced its corporate rebranding to AIBiotics Inc. with a new trading symbol AIBT, effective February 3, 2025. The company, which develops AI and robotics-enhanced technologies, focuses on scaling businesses across healthcare, manufacturing, and logistics sectors.
Recently, AIBiotics signed a letter of intent to acquire DigiTrax Entertainment Inc. in a $40 million deal, which includes seven U.S. patents in music AI technology, a $9 million music catalog, and strategic licensing agreements with major publishers.
AIBotics, a subsidiary of Ehave (EHVVF), has signed a letter of intent to acquire DigiTrax Entertainment in a $40 million transaction. The deal includes seven U.S. patents in music AI, a $9 million music catalog, and licensing agreements with leading publishers. DigiTrax's last funding round valued the company at $32 million.
The acquisition, targeted to close by February 28, 2025, will position DigiTrax as an AIBotics subsidiary. DigiTrax shareholders will receive newly designated preferred stock, common stock, and cash consideration. DigiTrax CEO Joseph Vangieri will retain his position and join AIBotics' board.
DigiTrax operates through three divisions: AI Innovation (featuring the KR38R platform), Karaoke Interactive Digital Media Platform, and Music Catalog Services. The company's AI technology is integrated with major digital audio workstations and has been adopted by platinum artists and major labels.
Ehave (OTC Pink: EHVVF) has announced its return to current SEC filing status and resumed trading on the OTC Pink Market. The company's existing shareholders will find their shares quoted on the OTC Pink Market without requiring any additional action. CEO Ben Kaplan emphasized his commitment to shareholders and expressed confidence in moving the company in a new direction in 2025. This development marks a significant milestone in the company's efforts to maintain transparency, regulatory compliance, and protect shareholder value.
Ehave, Inc. (EHVVF) has successfully completed phase one of its study with the University of Melbourne to investigate hallucinogen-persisting perception disorder (HPPD), a condition that may arise from psychedelics. The study aims to identify biomarkers that help determine individuals at risk of developing HPPD. Preliminary results show a significant occurrence of visual disturbances among participants, indicating potential links to anxiety and depression. Ehave plans to expand the research to include a broader participant base from the HPPD community, targeting the development of effective therapeutic solutions.
Ehave, Inc. announced FDA approval for its clinical study focusing on low-dose intravenous ketamine infusions for patients with Major Depression Disorder (MDD). The study, which involves 35 participants with inadequate responses to existing antidepressants, aims to analyze EEG changes during and after treatment. This marks a pivotal step in exploring ketamine's potential as a treatment for MDD, especially given the growing global prevalence of depression. Ehave seeks to address the limitations of current pharmacological options with its innovative approach.
Ehave, Inc. (OTC Pink: EHVVF) issued a shareholder letter detailing achievements in 2022 amid economic challenges, including inflation and rising interest rates. The company highlighted a $380 million triangular merger involving its subsidiary, Mycotopia Therapies, aimed at NASDAQ trading approval. Key milestones included the acquisition of Rejuv IV, now KetaDASH, which provides at-home ketamine treatments. Ehave also launched MetaHealthU, a platform for patient data integration, and MetaHealthYuru, an AI-driven mental health monitor. The company plans to expand its subsidiaries in 2023.
Ehave, Inc. (OTC Pink: EHVVF) announced that its KetaDASH subsidiary will receive its KetaDASH Mobile Unit in Miami Beach, Florida, on June 10, 2022. This custom medical van will facilitate in-home Ketamine IV treatments, providing real-time health data to enhance clinical outcomes. KetaDASH has already begun operations in Sacramento and San Francisco, offering managed services to streamline physician practices and improve patient care. CEO Ben Kaplan emphasized ketamine's potential for treating various psychological conditions, showcasing the company's commitment to innovative healthcare solutions.
Ehave, Inc. (EHVVF) has announced that its subsidiary, KetaDASH, will utilize precision medicine in psychedelic-assisted therapy through a partnership with HaluGen Life Sciences. This collaboration will employ a genetic testing kit to assess patients' genetic profiles and risk factors. The aim is to personalize treatment based on individual genetic variations, particularly focusing on gene mutations that influence responses to ketamine and other psychedelics. This innovative approach positions KetaDASH as a pioneer in integrating genetics into psychedelic therapy, enhancing patient outcomes and differentiating the company in a competitive market.
